Yuhan Corporation
Clinical trials sponsored by Yuhan Corporation, explained in plain language.
A South Korean pharmaceutical company developing drugs and vaccines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New generic combo pill for high blood pressure put to the test Results expected Sep 2026 (estimated)
- Healthy men needed to test experimental Drug's safety Results expected Mar 2027 (estimated)
- New drug YH32364 targets Hard-to-Treat cancers in first human trial Results expected Jun 2027 (estimated)
- New hope for chronic hives? experimental drug lesigercept enters Mid-Stage trial Results expected Jun 2027 (estimated)
-
New drug targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new drug called YH42946 in people with advanced solid tumors that have certain gene changes (HER2 or EGFR). The main goals are to check safety and see if the drug shrinks tumors. About 161 adults who have run out of standard options will take part.
Phase 1/2 • Sponsor: Yuhan Corporation • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New hope for HER2 cancers: first human trial launches
Disease control Recruiting nowThis early-phase trial tests an experimental drug called YH32367 in people with HER2-positive solid tumors that have spread or cannot be removed by surgery. The study has two parts: first, finding a safe dose, then testing that dose in specific cancer types like biliary tract can…
Phase 1/2 • Sponsor: Yuhan Corporation • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug YH32364 targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis study tests an experimental drug called YH32364 in adults with advanced solid tumors that have high levels of EGFR and have not responded to previous treatments. The trial has two parts: first, finding a safe dose in about 30 people, then testing that dose in 50 people with …
Phase 1/2 • Sponsor: Yuhan Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New hope for chronic hives? experimental drug lesigercept enters Mid-Stage trial
Disease control Recruiting nowThis study tests a new drug called lesigercept in 150 adults with chronic spontaneous urticaria (hives lasting 6+ months) that aren't controlled by standard antihistamines. Participants receive either lesigercept or a placebo injection. The main goal is to see if lesigercept redu…
Phase 2 • Sponsor: Yuhan Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC